Biotech industry well positioned for strong start to 2021

This week's Fierce Biotech is brought to you by Clarivate Analytics (US) LLC.

Trouble viewing? Click here.

Investments in biopharma hit record highs while R&D activity and deal-making remain robust

Biotech set for good start to 2021

Despite the disruption caused by the pandemic last year, the biotech industry have been able to raise record sums of capital, conclude biopartnering deals, and launch new medicines. As we push off the starting blocks of 2021, see how the industry is positioned:

Who raised the most funds for investment in 2020?
Who are the main investors driving innovation?
Which countries have raised the most for their innovations?
What is the climate for mergers, acquisitions and biopartnering?

Read more in our white paper: Biotech set for good start to 2021.

Decision Resources Group
DR/Decision Resources, LLC,
100 District Ave, Suite 213, Burlington, MA 01803
US: +1.855.380.4850 | EU: +44.20.7392.4081 |
APAC: +65.6909.5302
Email: questions@teamdrg.com

Personal data may be transferred to the United States, and could be subject to applicable laws. For further information about privacy, please see our policies page.

If you no longer wish to receive communications from Clarivate Analytics (US) LLC, please opt out here.

Want to reach 137,000+ Fierce Biotech subscribers with your own message?
Contact aalcover@questex.com or call 202-824-5074.

You are currently subscribed as newsletter@newslettercollector.com.
If you no longer wish to receive communications from Fierce Biotech's trusted partners, simply click here to unsubscribe .
Refer to our Privacy Policy.

Questex, LLC
685 3rd Avenue, 21st Floor
New York, NY 10017